Working Together to Find a Cure     Print Page | Close Window

Press Release

PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board

DALLAS and NEW YORK, April 7, 2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, appointed Robert Sandhaus, MD, Ph.D. to its Scientific Advisory Board (SAB). The appointed SAB will serve as a strategic resource to the company as it continues to develop and commercialize its proprietary plasma fractionation platform, Salt Diafiltration Process (SDF™), and its lead biologic candidate, SDF Alpha, its proprietary alpha-1 protease inhibitor (A1PI).

"We are delighted to have Dr. Sandhaus join our SAB," stated Steve Rouhandeh, PlasmaTech's Executive Chairman. "Dr. Sandhaus, a leading pulmonologist at National Jewish Health in Denver, has extensive experience with the plasma therapeutics industry and is a leader in the Alpha-1 Community. We look forward to leveraging their expertise and counsel as we advance corporate objectives and deliver on key research and operational goals," he continued.

"I am pleased to be invited to join PlasmaTech's SAB," said Dr. Sandhaus and further added that, "Harnessing the Company's SDF Process will result in continuing to provide patients with vital plasma-derived therapeutics to treat their deficiencies. With a strong strategic focus on Alpha-1 and its differentiating technology, PlasmaTech has the ability to create a paradigm shift in the plasma-derived therapeutics market. I look forward to working together to bringing this needed technology to market."

Robert (Sandy) Sandhaus, MD, Ph.D. is a professor of medicine at the National Jewish Health in Denver, CO. He is also the Clinical Director of the Alpha-1 Foundation ( and a Medical Director of AlphaNet, a disease management company focused on alpha-1 antitrypsin deficiency. Dr. Sandhaus has extensive experience in the pharmaceutical industry and is an expert in the pathogenesis of emphysema.

About Plasma Proteins and the SDF™ Process: The global market for drugs derived from human blood plasma fractionation is currently greater than US$15 billion, and is growing at a rate close to 10% annually. Despite this significant market opportunity, limited innovation in fractionation technology has occurred in decades. PTBI has developed and patented a new extraction process for plasma biologics that may fundamentally change the economics of blood plasma fractionation, and makes possible the extraction of several additional therapeutically useful plasma proteins. The Company believes that PlasmaTech's proprietary fractionation process is expected to significantly enhance yields of key value blood proteins, including alpha-1 antitrypsin, expanding market opportunities while greatly enhancing margins. The Company obtained rights to utilize and sub-license to other pharmaceuticals firms, the patented improved methods for the extraction of therapeutic biologics from human plasma. The Company believes that PlasmaTech's lead product opportunity, alpha-1 antitrypsin (ATT), will offer a potentially high revenue, short time-to-market respiratory product (AAT) for treatment of inherited COPD (pulmonary emphysema), among other indications. Additionally, the ability to extract several additional therapeutically useful and important proteins, due to the process being less destructive than historical fractionation processes, may enable the Company to seek new therapeutic applications and address high-value-added orphan indications.

About PlasmaTech: PlasmaTech is a biopharmaceutical company focused on advancing protein biologic therapies and oncology supportive care products. Exploiting two proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, and follow-on products in development. For more information, visit

Company and Media Contact:
Andre'a Lucca
Director of Communications
PlasmaTech Biopharmaceuticals, Inc.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, those relating to: the anticipated closing of, and the amount of the proceeds from, the private placement described in this press release, our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and ProctiGard, the global market for drugs derived from human blood plasma and its growth rate, expectations relating to AAT, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.